Clinical Trials Logo

Neoadjuvant Treatment clinical trials

View clinical trials related to Neoadjuvant Treatment.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05524012 Recruiting - Radiotherapy Clinical Trials

Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer

PRIMO
Start date: November 30, 2022
Phase:
Study type: Observational

This pilot study aims to trial multimodal early response assessment to enable therapy adaptions in the context of non-operative therapy strategies of locally advanced rectal cancer (LARC) for development of a non-invasive response prediction model.

NCT ID: NCT05382052 Recruiting - Clinical trials for Non Small Cell Lung Cancer Stage III

Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment

REAL-NADIM
Start date: June 17, 2022
Phase:
Study type: Observational

This is an observational, prospective, multicentre and nationwide study. The study enroll resectable stage IIIA non-small cell lung cancer patients that are going to receive neoadjuvant treatment in real world. The primary objective of this study is evaluating whether there is a significant association between ctDNA clearance (no detection of ctDNA) after neoadjuvant treatment and before surgery and progression free survival.

NCT ID: NCT05343325 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC

Start date: March 9, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of neoadjuvant low-dose radiotherapy combined with chemoimmunotherapy in resectable locally advanced head and neck squamous cell carcinoma. The eligible patients are scheduled to administered neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound paclitaxel and cisplatin for two cycles. Radical resection will be performed in 3-4 weeks after two cycles of neoadjuvant therapy. The overall primary study hypothesis is that the novel neoadjuvant combination regime improves the pathological complete response (pCR) rate, with tolerable side effects.

NCT ID: NCT05111860 Recruiting - Rectal Cancer Clinical Trials

Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy

Start date: November 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Prospectively Investigate the effectiveness and safety of neoadjuvant Bevacizumab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS mutant-type locally advanced rectal cancer

NCT ID: NCT04923620 Recruiting - Rectal Cancer Clinical Trials

Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy

Start date: October 20, 2021
Phase:
Study type: Observational [Patient Registry]

Prospectively Investigate the effectiveness and safety of neoadjuvant cetuximab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS wild-type locally advanced rectal cancer

NCT ID: NCT04280822 Recruiting - Surgery Clinical Trials

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

Start date: April 21, 2020
Phase: Phase 3
Study type: Interventional

The effect of neo-adjuvant immunochemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains unknown. One of our objectives is to evaluate whether the neo-adjuvant immunochemotherapy Toripalimab (JS001) with cisplatin and paclitaxel followed by right thoracic approach esophagectomy with total 2-field lymph node dissection improves the overall survival of thoracic esophageal cancer patients versus neo-adjuvant chemotherapy.

NCT ID: NCT03479814 Recruiting - Rectal Cancer Clinical Trials

Adaptive Individualized High-Dose Radiotherapy Analysis-REctum-1 (AIDA-RE-1)

Start date: August 1, 2016
Phase: N/A
Study type: Interventional

Aim of the study is to evaluate achievement of complete pathologic response (pCR) in high-risk rectal cancer treated with neoadjuvant concomitant chemotherapy plus adaptive-intensity modulated imaging-guided radiotherapy